Healthcare
Novo Nordisk A/S(NVO)
Live Price
Offline$45.88
+6.23% today
1Y Change
-36.20%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $1.24T
- Revenue Growth
- +6.4%
- EPS Growth
- +1.7%
- Dividend Yield
- 4.2%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novo Nordisk A/S (NVO) is a Healthcare stock with a market cap of $1.24T and listed on NYSE. The stock last traded around $45.88 and down 36.2% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +6.4%, EPS growth of +1.7%, a dividend yield of 4.2%. What stands out right now is revenue +6.4%, EPS +1.7%, free cash flow -58.4% with operating margin 41.3% and ROIC 29.5%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 12.1 and price/sales 4.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines NVO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.4% vs +7.6% peer median
Operating Margin
Above sector median
+41.3% vs +19.4% peer median
P/E
Below sector median
12.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.4% and EPS at +1.7%, with operating margin around 41.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.1% | +2.9% | -4.4% |
2026 Feb 4, 2026 | +11.1% | -8.2% | +3.3% | -17.2% |
2025 Nov 5, 2025 | +32.5% | -4.0% | +3.7% | -1.0% |
Benchmark Edge
NVO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVO Max Drawdown
-50.78%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVO and SPY.
Company Overview
Novo Nordisk A/S
New York Stock Exchange
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Leadership
- Maziar Mike Doustdar
- IPO Date
- Apr 30, 1981
- Employees
- 77.4k
- Street Address
- Novo Alle 1
- Mailing
- Bagsvaerd, 2880
- Region
- Bagsvaerd, DK
- Reporting Currency
- USD
- Investor Line
- 45 44 44 88 88
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.1
- EV/EBITDA
- 8.3
- Price/Sales
- 4.0
- Price/Book
- 6.4
Growth
- Revenue
- +6.4%
- EPS
- +1.7%
- Free Cash Flow
- -58.4%
Profitability
- Gross Margin
- 81.0%
- Operating Margin
- 41.3%
- Net Margin
- 33.1%
- ROE
- 61.1%
- ROIC
- 29.5%
Balance Sheet
- Debt/Equity
- 0.67
- Current Ratio
- 0.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.